<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04526951</url>
  </required_header>
  <id_info>
    <org_study_id>Oslo UH</org_study_id>
    <secondary_id>2018-002546-36</secondary_id>
    <secondary_id>2019/327</secondary_id>
    <nct_id>NCT04526951</nct_id>
  </id_info>
  <brief_title>TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)</brief_title>
  <acronym>TenCRAOS</acronym>
  <official_title>TENecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): A Randomized Placebo-controlled Trial of Early Systemic Tenecteplase Treatment in Patients With Central Retinal Artery Occlusion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TENecteplase in Central Retinal Artery Occlusion (TenCRAOS): A Prospective,&#xD;
      randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25&#xD;
      mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomization).&#xD;
&#xD;
      A Prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial&#xD;
      of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomization). At all&#xD;
      participating centers, ophthalmologists are involved in the diagnosis and visual outcome&#xD;
      measurements using a standardized protocol. The patients will be promptly examined by the&#xD;
      ophthalmologist. As soon as the CRAO is diagnosed by the ophthalmologist, the patients will&#xD;
      be managed in the stroke unit during treatment, monitoring, and medical investigations. After&#xD;
      treatment in the stroke unit, the patients will be re-examined by an ophthalmologist and a&#xD;
      neurologist as an out-patient at (30 ±5) and 90 (±15) days&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central retinal artery occlusion (CRAO) is an ophthalmologic emergency that, without prompt&#xD;
      revascularization, bears high risk of permanent blindness. The condition is typically the&#xD;
      result of an artery-to-artery embolism from a carotid plaque or cardio embolism. A recent&#xD;
      meta-analysis of observational data indicates that prompt revascularization with systemic&#xD;
      thrombolysis might improve outcome. A randomized controlled trial of early systemic&#xD;
      thrombolysis for CRAO is therefore warranted. The aim of this project is to assess the effect&#xD;
      of systemic tissue plasminogen activator tenecteplase versus placebo administered within 4.5&#xD;
      hours of CRAO onset in patients admitted to the participating hospitals in Europe. The main&#xD;
      endpoint is the proportion of patients with ≤ 0.7 logMAR visual acuity 30 (±5) days after&#xD;
      treatment, representing an improvement in visual acuity of at least 0.3 logMAR, equal to at&#xD;
      least 15 letters/three lines on a visual acuity chart. In addition, we will access&#xD;
      differences in visual field parameters and patient reported outcome measures between the&#xD;
      groups. This study is based on a broad collaboration and interaction between leading&#xD;
      ophthalmologists and neurologists in European centres.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomisation). At all participating centers, ophthalmologists are involved in the diagnosis and visual outcome measurements using a standardized protocol. The patients will be promptly examined by the ophthalmologist. As soon as the CRAO is diagnosed by the ophthalmologist, the patients will be managed in the stroke unit during treatment, monitoring, and medical investigations. After treatment in the stroke unit, the patients will be re-examined by an ophthalmologist and a neurologist as an out-patient at (30 ±5) and 90 (±15) days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with ≤ 0.7 logMAR visual acuity in the affected eye at 30 (±5) days after treatment, representing an improvement in visual acuity of at least 0.3 logMAR (intention-to-treat (ITT) analysis).</measure>
    <time_frame>30 (±5) days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≤ 0.5 logMAR visual acuity in the affected eye at 30 (±5) and 90 (±15) days.</measure>
    <time_frame>30 (±5) and 90 (±15) days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean improvement in logMAR visual acuity in the affected eye from baseline to 30 (±5) and 90 (±15) days.</measure>
    <time_frame>30 (±5) and 90 (±15) days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with visual recovery (logMAR ≤ 0.7) and (logMAR ≤ 0.5) in the affected eye 30 (±5) and 90 (±15) days in patients who were treated with tenecteplase within 3 hours of onset</measure>
    <time_frame>30 (±5) and 90 (±15) days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of test points seen (of 100) on monocular Esterman perimetry at 30 (±5) and 90 (±15) days</measure>
    <time_frame>30 (±5) and 90 (±15) days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute ischemic lesions on follow-up on diffusion-weighted (DWI) MRI or on brain CT at baseline and 24hrs.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale score (NIHSS) at 24hrs and discharge.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale score (mRS) at discharge, 30 (±5) and 90 days (±15) days.</measure>
    <time_frame>Discharge, 30 (±5) and 90 days (±15) days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score on National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) at 30 (±5) and 90 (±15) days</measure>
    <time_frame>30 (±5) and 90 (±15) days</time_frame>
    <description>Visual function related quality of life at 30 and 90 days. Measures the dimensions of self-reported vision-targeted health status that are most important for persons who have chronic eye diseases. 100 = best possible, 0 = worst possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score on EQ-5D at 30 (±5) and 90 (±15) days</measure>
    <time_frame>30 (±5) and 90 (±15) days</time_frame>
    <description>Quality of life reported at 30 and 90 days. Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of ocular neovascularisation at 30 (±5) and 90 (±15) days</measure>
    <time_frame>30 (±5) and 90 (±15) days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>All-cause and stroke-related death at discharge, 30 (±5) and 90 (±15) days.</measure>
    <time_frame>Discharge assessed up to 7 days , 30 (±5) and 90 (±15) days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with any intracranial haemorrhage at 24 hrs</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with symptomatic intracranial haemorrhage until discharge.</measure>
    <time_frame>at discharge, assessed up to 7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with complications such as systemic bleeding at 24 hrs, discharge and 30 (±5) days</measure>
    <time_frame>24 hours, at discharge assessed up to 7 days and 30 (±5) days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Other serious adverse events</measure>
    <time_frame>24 hours, at discharge, 30 (±5) days and 90 days (±15) days.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>24 hours, at discharge assessed up to 7 days, 30 (±5) days and 90 days (±15) days.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Retrobulbar spot sign detection using Duplex/Doppler ultrasound at baseline, point-of-care ultrasound (POCUS)</measure>
    <time_frame>30 (±5) and 90 (±15) days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Retrobulbar spot sign and central retinal artery recanalisation using Duplex/Doppler ultrasound at 24h and discharge</measure>
    <time_frame>24 hours and at discharge assessed up to 7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Macular optical coherence tomography (OCT) volume scans and macular OCT angiography (OCT-A) at 30 and 90 days</measure>
    <time_frame>30 (±5) and 90 (±15) days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Central Retinal Artery Occlusion</condition>
  <arm_group>
    <arm_group_label>Tenecteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The total dose of tenecteplase is 0.25 mg/kg body weight, maximum 25 mg. The total dose will be given as an intravenous bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acetylsalicylic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one tablet of aspirin 300 mg Other Name: Aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous injection of Tenecteplase and one dose of placebo tablet</intervention_name>
    <description>Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)</description>
    <arm_group_label>Tenecteplase</arm_group_label>
    <other_name>Metalyse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>One tablet of Acetylsalicylic Acid and one dose of IV placebo</intervention_name>
    <description>300 mg Acetylsalisylic acid</description>
    <arm_group_label>acetylsalicylic acid</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-arteritic central retinal artery occlusion with ≥ 1.0 logMAR visual acuitiy and&#xD;
             symptoms lasting less than 4.5 hours.&#xD;
&#xD;
          2. Ability to administer the Investigator Medicinal Product (IMP) within 4.5 hours of&#xD;
             symptom onset.&#xD;
&#xD;
          3. Age ≥18 years.&#xD;
&#xD;
          4. Informed written consent of the patient.&#xD;
&#xD;
          5. A woman of childbearing potential (WOCBP) must confirm that in her opinion, she cannot&#xD;
             be pregnant, OR if there is a possibility that she is pregnant, a negative pregnancy&#xD;
             test must be confirmed before any IMP is given.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No other active intervention targeting CRAO.&#xD;
&#xD;
          2. Branch retinal artery occlusion, cilioretinal artery supplying the macula, combined&#xD;
             arterial-venous occlusion, proliferative diabetic retinopathy, elevated intraocular&#xD;
             pressure (&gt; 30 mmHg) or clinical suspicion of ophthalmic artery occlusion occlusion&#xD;
             (e.g. choroidal nonperfusion, absence of cherry red spot, no light perception).&#xD;
&#xD;
          3. Systemic diseases; severe general diseases, systemic arterial hypertension (blood&#xD;
             pressure &gt;185/110 mmHg), despite medical therapy, or clinical suspicion of acute&#xD;
             systemic inflammation.&#xD;
&#xD;
          4. Presence of intracranial haemorrhage on brain MRI/CT.&#xD;
&#xD;
          5. Medical history: heart attack within the last 6 weeks, intracerebral bleeding or&#xD;
             neurosurgical operation within the last 4 weeks, therapy with anticoagulation,&#xD;
             allergic reaction to contrast agent, hemorrhagic diathesis, aneurysms, inflammatory&#xD;
             vascular diseases (eg, giant cell arteritis, granulomatosis with polyangitis),&#xD;
             endocarditis, or gastric ulcer.&#xD;
&#xD;
          6. No willingness and ability of the patient to participate in all follow-up&#xD;
             examinations.&#xD;
&#xD;
          7. Pregnancy (if suspicion of pregnancy s-hCG or u-hCG must be negative).&#xD;
&#xD;
          8. Allergy or intolerance to any ingredients of IMP or placebo or gentamicin.&#xD;
&#xD;
          9. Other conditions / circumstances likely to lead to poor treatment adherence (eg,&#xD;
             history of poor compliance, alcohol or drug dependency, no fixed abode).&#xD;
&#xD;
         10. Significant bleeding disorder either at present or within the past 6 months.&#xD;
&#xD;
         11. Effective oral anticoagulant treatment, eg, warfarin sodium (INR &gt;1.3).&#xD;
&#xD;
         12. Effective anticoagulant treatment with heparin or low molecular weight heparin the&#xD;
             last 48 hours.&#xD;
&#xD;
         13. Any history of central nervous system damage (ie, neoplasm, aneurysm, intracranial or&#xD;
             spinal surgery).&#xD;
&#xD;
         14. Known hemorrhagic diathesis.&#xD;
&#xD;
         15. Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2&#xD;
             months (this includes any trauma associated with acute myocardial infarction).&#xD;
&#xD;
         16. Recent non-compressible vessel puncture within 2 weeks.&#xD;
&#xD;
         17. Recent trauma to the head or cranium.&#xD;
&#xD;
         18. Prolonged cardiopulmonary resuscitation (&gt;2 minutes) within the past 2 weeks.&#xD;
&#xD;
         19. Acute pericarditis and/or subacute bacterial endocarditis.&#xD;
&#xD;
         20. Acute pancreatitis.&#xD;
&#xD;
         21. Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension&#xD;
             (oesophageal varices) and active hepatitis.&#xD;
&#xD;
         22. Active peptic ulceration.&#xD;
&#xD;
         23. Arterial aneurysm and known arterial/venous malformation.&#xD;
&#xD;
         24. Neoplasm with increased bleeding risk.&#xD;
&#xD;
         25. Any known history of hemorrhagic stroke or stroke of unknown origin.&#xD;
&#xD;
         26. Known history of ischemic stroke or transient ischemic attack in the preceding 3&#xD;
             months.&#xD;
&#xD;
         27. Dementia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Hege Aamodt</last_name>
    <phone>+47 23074976</phone>
    <email>a.h.aamodt@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Vanacker</last_name>
      <phone>+32 3 830 52 02</phone>
      <email>peter.vanacker@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Søren Due, Prof</last_name>
      <phone>+45 97 66 00 00</phone>
      <email>s.due@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Ziegler, MD PhD AProf</last_name>
      <phone>+45 70 11 31 31</phone>
      <email>clausimo@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Toke Bek, MD PhD Prof</last_name>
      <phone>+45 70 11 31 31</phone>
      <email>toke.bek@mail.tele.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Toke Bek, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas C Truelsen, MD PhD</last_name>
      <phone>+4521810068</phone>
      <email>Thomas.clement.truelsen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petra Iljäs, MD PhD</last_name>
      <phone>+358 9 4711</phone>
      <email>Petra.Ijas@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospita</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Strbian, Prof</last_name>
      <phone>+358 9 4711</phone>
      <email>daniel.strbian@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Petra Iljäs</last_name>
      <email>Petra.Ijas@hus.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauli Ylikotila</last_name>
      <phone>+358 2 3130000</phone>
      <email>pauli.ylikotila@tyks.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sean Murphy, MD, PhD</last_name>
      <phone>+353 1 803 200</phone>
      <email>sean.murphy@mater.ie</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jurgita Valalkiene, A/Prof MD</last_name>
      <phone>+370 52365221</phone>
      <email>jurgita.valaikiene@santa.lt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sørlandet Hospital Trust</name>
      <address>
        <city>Arendal</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnstein Tveiten, MD PhD</last_name>
      <phone>+4790 61 06 00</phone>
      <email>arnstein.tveiten@sshf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrej Khanevski, MD, PhD</last_name>
      <phone>+4755975000</phone>
      <email>andrej.netland.khanevski@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Prof. Jørgen Krohn, MD,PhD,Prof</last_name>
      <phone>47 55975000</phone>
      <email>jorgen.gitlesen.krohn@helse-bergen.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nordland Hospital Trust</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Carlsson, MD</last_name>
      <phone>+4792881130</phone>
      <email>maria.carlsson@nordlandssykehuset.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vestre Viken Hospital Trust Drammen</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingvild Nakstad, MD</last_name>
      <phone>+4795815868</phone>
      <email>uxnaibt@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Østfold Hospital Trust Kalnes</name>
      <address>
        <city>Grålum</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Ratajczak-Tretel, MD</last_name>
      <phone>+4741597406</phone>
      <email>Barbara.Ratajczak@so-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Innlandet Hospital Trust</name>
      <address>
        <city>Lillehammer</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anette Huuse Farmen, MD PhD</last_name>
      <phone>+4792201208</phone>
      <email>Anette.Huuse.Farmen@sykehuset-innlandet.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordmøre and Romsdal Regional Hospital</name>
      <address>
        <city>Molde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Åse Hagen Morsund, MD, PhD</last_name>
      <phone>+4747756360</phone>
      <email>ase.hagen.morsund@helse-mr.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helse Nord Trøndelag Trust</name>
      <address>
        <city>Namsos</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Schüler, MD</last_name>
      <phone>+4774215535</phone>
      <email>stephan.schüler@helse-nordtrondelag.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Hege Aamodt, MD PhD</last_name>
      <phone>+4723074976</phone>
      <email>a.h.aamodt@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Stephen J Ryan, MD</last_name>
      <phone>+47 45109664</phone>
      <email>sterya@ous-hf.no</email>
    </contact_backup>
    <investigator>
      <last_name>Morten C Moe, MD PhD Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Øystein K Jørstad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristian L Kraglund, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Telemark Hospital Trust</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Håkon Tobro, MD</last_name>
      <phone>+4797024796</phone>
      <email>Hakon.tobro@sthf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Kurz, Prof</last_name>
      <phone>+47 47246847</phone>
      <email>friedrich.martin.wilhelm.kurz@sus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway, Tromsø</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stein-Harald Johnsen, A/Prof MD</last_name>
      <phone>+4792864490</phone>
      <email>Stein.Harald.Johnsen@unn.no</email>
    </contact>
    <contact_backup>
      <last_name>Geir Bertelsen, MD PhD</last_name>
      <phone>+47 77 62 60 00</phone>
      <email>Geir.Bertelsen@unn.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St Olav University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanne Ellekjær, MD, PhD</last_name>
      <phone>+47 41562687</phone>
      <email>hanne.ellekjar@ntnu.no</email>
    </contact>
    <contact_backup>
      <last_name>Dordi Austeng, MD, PhD</last_name>
      <phone>+47 72573000</phone>
      <email>dordi.austeng@stolav.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vestfold Hospital Trust</name>
      <address>
        <city>Tønsberg</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristian Jenssen, MD</last_name>
      <phone>+47 33 34 20 00</phone>
      <email>kristian.jenssen@siv.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário de São João</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricardo Soares Reis</last_name>
      <phone>+351 22 551 2100</phone>
      <email>ricardo.soares.reis@chsj.min-sau</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Mazya, MD PhD</last_name>
      <phone>+46709720277</phone>
      <email>michael.mazya@karolinska.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Ireland</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Anne Hege Aamodt</investigator_full_name>
    <investigator_title>Senior Consultant, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>thrombolysis tenecteplase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Artery Occlusion</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

